FABIO ALBUQUERQUE MARCHI
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina
LIM/03 - Laboratório de Medicina Laboratorial, Hospital das Clínicas, Faculdade de Medicina
LIM/03 - Laboratório de Medicina Laboratorial, Hospital das Clínicas, Faculdade de Medicina
5 resultados
Resultados de Busca
Agora exibindo 1 - 5 de 5
- New Insights into the Impact of Human Papillomavirus on Oral Cancer in Young Patients: Proteomic Approach Reveals a Novel Role for S100A8(2023) MIRANDA-GALVIS, Marisol; SOARES, Carolina Carneiro; CARNIELLI, Carolina Moretto; BUTTURA, Jaqueline Ramalho; SA, Raisa Sales de; KAMINAGAKURA, Estela; MARCHI, Fabio Albuquerque; LEME, Adriana Franco Paes; PINTO, Clovis A. Lopes; SANTOS-SILVA, Alan Roger; CASTILHO, Rogerio Moraes; KOWALSKI, Luiz Paulo; SQUARIZE, Cristiane HelenaHuman papillomavirus (HPV) infection has recently been linked to a subset of cancers affecting the oral cavity. However, the molecular mechanisms underlying HPV-driven oral squamous cell carcinoma (OSCC) onset and progression are poorly understood. Methods: We performed MS-based proteomics profiling based on HPV status in OSCC in young patients, following biological characterization and cell assays to explore the proteome functional landscape. Results: Thirty-nine proteins are differentially abundant between HPV (+) and HPV (-) OSCC. Among them, COPS3, DYHC1, and S100A8 are unfavorable for tumor recurrence and survival, in contrast to A2M and Serpine1, low levels of which show an association with better DFS. Remarkably, S100A8 is considered an independent prognostic factor for lower survival rates, and at high levels, it alters tumor-associated immune profiling, showing a lower proportion of M1 macrophages and dendritic cells. HPV (+) OSCC also displayed the pathogen-associated patterns receptor that, when activated, triggered the S100A8 and NF?B inflammatory responses. Conclusion: HPV (+) OSCC has a peculiar microenvironment pattern distinctive from HPV (-), involving the expression of pathogen-associated pattern receptors, S100A8 overexpression, and NF?B activation and responses, which has important consequences in prognosis and may guide therapeutic decisions.
- Discovery of Novel miRNAs in Colorectal Cancer: Potential Biological Roles and Clinical Utility(2023) MINUTENTAG, Iael Weissberg; SENEDA, Ana Laura; BARROS-FILHOS, Mateus C.; CARVALHO, Marcio de; SOUZA, Vanessa G. P.; HASIMOTO, Claudia N.; MORAES, Marcelo P. T.; MARCHI, Fabio A.; LAM, Wan L.; REIS, Patricia P.; DRIGO, Sandra A.Deregulated miRNAs are associated with colorectal cancer (CRC), with alterations depending on the tumor location. Novel tissue-specific miRNAs have been identified in different tumors and are associated with cancer. We used miRMaster to identify novel miRNAs in CRC from the TCGA and GEO data (discovery and validation groups). We used TCGA data from five tissues to analyze miRNA tissue specificity. miRDB was used to predict miRNA targets, and the UCSC Xena Browser was used to evaluate target expression. After successive analyses, we identified 15 novel miRNAs with the same expression patterns in CRC in both the discovery and validation groups. Four molecules (nov-miR-13844-5p, nov-miR-7154-5p, nov-miR-5035-3p, and nov-miR-590-5p) were differentially expressed in proximal and distal CRC. The nov-miR-3345-5p and nov-miR-13172-3p, which are upregulated in tumors, are only expressed in colorectal tissues. These molecules have been linked to a worse prognosis in right-sided colon and rectal carcinomas. An analysis revealed an association between eight novel miRNAs and 81 targets, mostly cancer-related genes, with varying expression based on tumor location. These findings provide new miRNAs with potential biological relevance, molecular biomarkers, and therapeutic targets for CRC treatment.
- microRNAs associated with metastatic potential in salivary gland mucoepidermoid carcinoma(2023) TREVIZANI, Maria Eduarda S.; OLIVEIRA, Katia K.; MARCHI, Fabio A.; BIZINELLI, Daniela; MARIANO, Fernanda V.; NAGANO, Cibele P.; COSTA, Felipe A.; PINTO, Clovis A.; KOWALSKI, Luiz P.; LOURENCO, Silvia V.; COUTINHO-CAMILLO, Claudia M.
- Advances in the Molecular Landscape of Lung Cancer Brain Metastasis(2023) SOUZA, Vanessa G. P.; ARAUJO, Rachel Paes de; SANTESSO, Mariana R.; SENEDA, Ana Laura; MINUTENTAG, Iael W.; FELIX, Tainara Francini; HAMAMOTO, Pedro Tadao; PEWARCHUK, Michelle E.; BROCKLEY, Liam J.; MARCHI, Fabio A.; LAM, Wan L.; DRIGO, Sandra A.; REIS, Patricia P.Simple Summary Patients with lung cancer have high rates of brain metastasis (BM). Despite available therapies, patient prognosis is poor. Studies have shown genetic alterations associated with the metastatic spread of lung cancer cells. However, the precise mechanisms governing BM are still unclear. In this review, we comprehensively describe the major steps of metastatic spread of lung cancer to the brain, addressing the influence of the tumor microenvironment and the molecular determinants of progression. Furthermore, we highlight the advances in the molecular diagnostics of BM by liquid biopsies and discuss novel treatment strategies. Lung cancer is one of the most frequent tumors that metastasize to the brain. Brain metastasis (BM) is common in advanced cases, being the major cause of patient morbidity and mortality. BMs are thought to arise via the seeding of circulating tumor cells into the brain microvasculature. In brain tissue, the interaction with immune cells promotes a microenvironment favorable to the growth of cancer cells. Despite multimodal treatments and advances in systemic therapies, lung cancer patients still have poor prognoses. Therefore, there is an urgent need to identify the molecular drivers of BM and clinically applicable biomarkers in order to improve disease outcomes and patient survival. The goal of this review is to summarize the current state of knowledge on the mechanisms of the metastatic spread of lung cancer to the brain and how the metastatic spread is influenced by the brain microenvironment, and to elucidate the molecular determinants of brain metastasis regarding the role of genomic and transcriptomic changes, including coding and non-coding RNAs. We also present an overview of the current therapeutics and novel treatment strategies for patients diagnosed with BM from NSCLC.
- DNA methylation-based depiction of the immune microenvironment and immune-associated long non-coding RNAs in oral cavity squamous cell carcinomas(2023) CALANCA, Naiade; FRANCISCO, Ana Lucia Noronha; BIZINELLI, Daniela; KUASNE, Hellen; BARROS FILHO, Mateus Camargo; FLORES, Bianca Campos Troncarelli; PINTO, Clovis Antonio Lopes; RAINHO, Claudia Aparecida; SOARES, Milena Botelho Pereira; MARCHI, Fabio Albuquerque; KOWALSKI, Luiz Paulo; ROGATTO, Silvia ReginaOral cavity squamous cell carcinoma (OSCC) is a complex and dynamic disease characterized by clinicopathological and molecular heterogeneity. Spatial and temporal heterogeneity of cell subpopulations has been associated with cancer progression and implicated in the prognosis and therapy response. Emerging evidence indicates that aberrant epigenetic profiles in OSCC may foster an immunosuppressive tumor microenvironment by modulating the expression of immune-related long non-coding RNAs (lncRNAs). DNA methylation analysis was performed in 46 matched OSCC and normal adjacent tissue samples using a genome-wide platform (Infinium HumanMethylation450 BeadChip). Reference-based computational deconvolution (MethylCIBERSORT) was applied to infer the immune cell composition of the bulk samples. The expression levels of genes encoding immune markers and differentially methylated lncRNAs were investigated using The Cancer Genome Atlas dataset. OSCC specimens presented distinct immune cell composition, including the enrichment of monocyte lineage cells, natural killer cells, cytotoxic T-lymphocytes, regulatory T-lymphocytes, and neutrophils. In contrast, B-lymphocytes, effector T-lymphocytes, and fibroblasts were diminished in tumor samples. The hypomethylation of three immune-associated lncRNAs (MEG3, MIR155HG, and WFDC21P) at individual CpG sites was confirmed by bisulfite-pyrosequencing. Also, the upregulation of a set of immune markers (FOXP3, GZMB, IL10, IL2RA, TGFB, IFNG, TDO2, IDO1, and HIF1A) was detected. The immune cell composition, immune markers alteration, and dysregulation of immune-associated lncRNAs reinforce the impact of the immune microenvironment in OSCC. These concurrent factors contribute to tumor heterogeneity, suggesting that epiimmunotherapy could be an efficient alternative to treat OSCC.